Abpro Holdings ( (ABP) ) has provided an announcement.
On February 21, 2025, Abpro Holdings released an investor presentation highlighting its robust pipeline of antibody therapies, which includes promising candidates like ABP-102 for HER2+ cancers and ABP-201 for wet AMD and DME. The presentation underscored strategic partnerships, including a significant collaboration with Celltrion, fully funding ABP-102 development, and emphasized Abpro’s sophisticated technology platforms that position it strongly in the competitive biotech sector.
More about Abpro Holdings
Abpro Holdings, Inc. operates in the biotechnology industry, focusing on the discovery and engineering of antibody therapies. The company utilizes platforms like DiversImmune and MultiMab to develop novel antibodies, targeting high-value markets such as oncology and ophthalmology.
YTD Price Performance: -40.13%
Average Trading Volume: 757,349
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $48.85M
See more data about ABP stock on TipRanks’ Stock Analysis page.